In a late-stage trial, Novavax's prototype COVID-19 vaccine increased neutralizing antibody titers up to 34 times higher than primary vaccination among adults, with a "significant boost" against omicron variants and subvariants BA.1, BA.2 and BA.5.
In the same study, one booster shot increased neutralizing titers 2.7-fold among teenagers between 12 and 17 years old, Novavax said Oct. 12.
The vaccine-maker, which began distributing its COVID-19 vaccine after gaining the FDA and CDC's authorization in July, said the prototype booster doses were well tolerated and side effects were mainly mild to moderate.